Influence of conflicts of interest on public positions in the COVID-19 era, the case of Gilead Sciences.
Identifieur interne : 000971 ( Main/Corpus ); précédent : 000970; suivant : 000972Influence of conflicts of interest on public positions in the COVID-19 era, the case of Gilead Sciences.
Auteurs : Y. Roussel ; D. RaoultSource :
- New microbes and new infections [ 2052-2975 ] ; 2020.
Abstract
Funding and gifts from the pharmaceutical industry have an influence on the decisions made by physicians and medical experts. In the context of the coronavirus disease 2019 epidemic, several treatments are available to treat patients infected with the virus. Some are protected by patents, such as remdesivir, others0020stare not, such as hydroxychloroquine. We wanted to observe the possible correlation between the fact, for an academic doctor in infectious diseases, of having benefited from funding by Gilead Sciences, producer of remdesivir, and the public positions taken by this doctor towards hydroxychloroquine. Our results show a correlation (Spearman test, p = 0.017) between the amount received from the Gilead Sciences company and public opposition to the use of hydroxychloroquine in France. This should open up the debate on the role of the interest links of doctors with pharmaceutical companies in the medical and scientific public debate.
DOI: 10.1016/j.nmni.2020.100710
PubMed: 33088575
PubMed Central: PMC7558214
Links to Exploration step
pubmed:33088575Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Influence of conflicts of interest on public positions in the COVID-19 era, the case of Gilead Sciences.</title><author><name sortKey="Roussel, Y" sort="Roussel, Y" uniqKey="Roussel Y" first="Y" last="Roussel">Y. Roussel</name><affiliation><nlm:affiliation>Institut Hospitalo-universitaire Méditerranée Infection, Marseille, France.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Aix Marseille Université, Institut de Recherche pour le Développement (IRD), Assistance Publique-Hôpitaux de Marseille, Evolution Phylogénie et Infections (MEPHI), Marseille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Raoult, D" sort="Raoult, D" uniqKey="Raoult D" first="D" last="Raoult">D. Raoult</name><affiliation><nlm:affiliation>Institut Hospitalo-universitaire Méditerranée Infection, Marseille, France.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Aix Marseille Université, Institut de Recherche pour le Développement (IRD), Assistance Publique-Hôpitaux de Marseille, Evolution Phylogénie et Infections (MEPHI), Marseille, France.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:33088575</idno><idno type="pmid">33088575</idno><idno type="doi">10.1016/j.nmni.2020.100710</idno><idno type="pmc">PMC7558214</idno><idno type="wicri:Area/Main/Corpus">000971</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000971</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Influence of conflicts of interest on public positions in the COVID-19 era, the case of Gilead Sciences.</title><author><name sortKey="Roussel, Y" sort="Roussel, Y" uniqKey="Roussel Y" first="Y" last="Roussel">Y. Roussel</name><affiliation><nlm:affiliation>Institut Hospitalo-universitaire Méditerranée Infection, Marseille, France.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Aix Marseille Université, Institut de Recherche pour le Développement (IRD), Assistance Publique-Hôpitaux de Marseille, Evolution Phylogénie et Infections (MEPHI), Marseille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Raoult, D" sort="Raoult, D" uniqKey="Raoult D" first="D" last="Raoult">D. Raoult</name><affiliation><nlm:affiliation>Institut Hospitalo-universitaire Méditerranée Infection, Marseille, France.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Aix Marseille Université, Institut de Recherche pour le Développement (IRD), Assistance Publique-Hôpitaux de Marseille, Evolution Phylogénie et Infections (MEPHI), Marseille, France.</nlm:affiliation></affiliation></author></analytic><series><title level="j">New microbes and new infections</title><idno type="ISSN">2052-2975</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Funding and gifts from the pharmaceutical industry have an influence on the decisions made by physicians and medical experts. In the context of the coronavirus disease 2019 epidemic, several treatments are available to treat patients infected with the virus. Some are protected by patents, such as remdesivir, others0020stare not, such as hydroxychloroquine. We wanted to observe the possible correlation between the fact, for an academic doctor in infectious diseases, of having benefited from funding by Gilead Sciences, producer of remdesivir, and the public positions taken by this doctor towards hydroxychloroquine. Our results show a correlation (Spearman test, p = 0.017) between the amount received from the Gilead Sciences company and public opposition to the use of hydroxychloroquine in France. This should open up the debate on the role of the interest links of doctors with pharmaceutical companies in the medical and scientific public debate.</div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33088575</PMID><DateRevised><Year>2020</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2052-2975</ISSN><JournalIssue CitedMedium="Print"><Volume>38</Volume><PubDate><Year>2020</Year><Month>Nov</Month></PubDate></JournalIssue><Title>New microbes and new infections</Title><ISOAbbreviation>New Microbes New Infect</ISOAbbreviation></Journal><ArticleTitle>Influence of conflicts of interest on public positions in the COVID-19 era, the case of Gilead Sciences.</ArticleTitle><Pagination><MedlinePgn>100710</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.nmni.2020.100710</ELocationID><Abstract><AbstractText>Funding and gifts from the pharmaceutical industry have an influence on the decisions made by physicians and medical experts. In the context of the coronavirus disease 2019 epidemic, several treatments are available to treat patients infected with the virus. Some are protected by patents, such as remdesivir, others0020stare not, such as hydroxychloroquine. We wanted to observe the possible correlation between the fact, for an academic doctor in infectious diseases, of having benefited from funding by Gilead Sciences, producer of remdesivir, and the public positions taken by this doctor towards hydroxychloroquine. Our results show a correlation (Spearman test, p = 0.017) between the amount received from the Gilead Sciences company and public opposition to the use of hydroxychloroquine in France. This should open up the debate on the role of the interest links of doctors with pharmaceutical companies in the medical and scientific public debate.</AbstractText><CopyrightInformation>© 2020 Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Roussel</LastName><ForeName>Y</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institut Hospitalo-universitaire Méditerranée Infection, Marseille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Aix Marseille Université, Institut de Recherche pour le Développement (IRD), Assistance Publique-Hôpitaux de Marseille, Evolution Phylogénie et Infections (MEPHI), Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raoult</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institut Hospitalo-universitaire Méditerranée Infection, Marseille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Aix Marseille Université, Institut de Recherche pour le Développement (IRD), Assistance Publique-Hôpitaux de Marseille, Evolution Phylogénie et Infections (MEPHI), Marseille, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>New Microbes New Infect</MedlineTA><NlmUniqueID>101624750</NlmUniqueID><ISSNLinking>2052-2975</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID1-19</Keyword><Keyword MajorTopicYN="N">Conflicts of interest</Keyword><Keyword MajorTopicYN="N">SARS-COV-2</Keyword><Keyword MajorTopicYN="N">hydroxychloroquine</Keyword><Keyword MajorTopicYN="N">remdesivir</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>05</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>05</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>06</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>22</Day><Hour>5</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33088575</ArticleId><ArticleId IdType="doi">10.1016/j.nmni.2020.100710</ArticleId><ArticleId IdType="pii">S2052-2975(20)30062-7</ArticleId><ArticleId IdType="pmc">PMC7558214</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Med (N Y). 2020 Jun 5;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32838355</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 May 7;382(19):1787-1799</Citation><ArticleIdList><ArticleId IdType="pubmed">32187464</ArticleId></ArticleIdList></Reference><Reference><Citation>CMAJ. 1993 Nov 15;149(10):1401-7</Citation><ArticleIdList><ArticleId IdType="pubmed">8221424</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation><ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2004 Oct 28;351(18):1885-90</Citation><ArticleIdList><ArticleId IdType="pubmed">15509823</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Health Serv Res. 2018 Apr 2;18(1):236</Citation><ArticleIdList><ArticleId IdType="pubmed">29609611</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2003 Jul 9;290(2):252-5</Citation><ArticleIdList><ArticleId IdType="pubmed">12851281</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Cell Biol. 2020 May 18;12(4):322-325</Citation><ArticleIdList><ArticleId IdType="pubmed">32236562</ArticleId></ArticleIdList></Reference><Reference><Citation>Travel Med Infect Dis. 2020 May - Jun;35:101738</Citation><ArticleIdList><ArticleId IdType="pubmed">32387409</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Intern Med. 1998 Mar;13(3):151-4</Citation><ArticleIdList><ArticleId IdType="pubmed">9541370</ArticleId></ArticleIdList></Reference><Reference><Citation>Travel Med Infect Dis. 2020 Mar - Apr;34:101663</Citation><ArticleIdList><ArticleId IdType="pubmed">32289548</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 May 16;395(10236):1569-1578</Citation><ArticleIdList><ArticleId IdType="pubmed">32423584</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Bioeth. 2003 Summer;3(3):39-46</Citation><ArticleIdList><ArticleId IdType="pubmed">14594489</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Intern Med. 2016 Aug 1;176(8):1114-1122</Citation><ArticleIdList><ArticleId IdType="pubmed">27322350</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2003 May 31;326(7400):1178-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12775618</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med. 2001 May;110(7):551-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11347622</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation><ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000971 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000971 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:33088575
|texte= Influence of conflicts of interest on public positions in the COVID-19 era, the case of Gilead Sciences.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:33088575" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |